Downloads provided by UsageCounts
{"references": ["Rader DJ, Maratos-Flier E, Nguyen A, Hom D, Ferriere M, Li Y, Kompa J, Martic M, Hinder M, Basson CT, Yowe D, Diener J, Goldfine AB; CLLF580X2102 study team. LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in obese adults with modest hypertriglyceridemia. J Clin Endocrinol Metab. 2021 Aug 25:dgab624. doi: 10.1210/clinem/dgab624. Epub ahead of print. PMID: 34431493."]}
Supplemental information to the manuscript entitled "LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults with Modest Hypertriglyceridemia"
Fibroblast growth factor 21 (FGF21), Hypertriglyceridemia, Obesity, Nonalcoholic Fatty Liver Diseases (NAFLD), Metabolism
Fibroblast growth factor 21 (FGF21), Hypertriglyceridemia, Obesity, Nonalcoholic Fatty Liver Diseases (NAFLD), Metabolism
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 5 | |
| downloads | 3 |

Views provided by UsageCounts
Downloads provided by UsageCounts